)
PetMed Express (PETS) investor relations material
PetMed Express Q4 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Fiscal year 2026 marked a pivotal period with significant financial, operational, and cultural improvements aimed at long-term sustainability.
Substantial progress was made in stabilizing the core business and regaining regulatory compliance in the second half of the year.
Leadership changes included a new Chief Growth Officer and key internal promotions to strengthen operations.
Employee benefits were expanded, and satisfaction ratings increased, reflecting a renewed focus on culture.
The board rejected two unsolicited acquisition proposals in December 2025, opting to remain independent but open to future offers.
Financial highlights
Net sales for FY2026 were $179 million, down 21.1% year-over-year; Q4 net sales were $42.8 million, down 15.6% from the prior year, mainly due to lower prescription medication sales.
Q4 gross profit was $13.9 million (32.6% of sales), up 270 basis points year-over-year due to a sales tax settlement.
Q4 net loss was $4.1 million ($0.19 per share), improved from $11.6 million loss last year; full-year net loss was $57.3 million ($2.74 per share), up from $6.3 million loss in the prior year, driven by a $26.7 million goodwill impairment and higher non-recurring expenses.
Adjusted EBITDA loss for FY2026 was $15.4 million, compared to positive $0.7 million in the prior year.
Cash and cash equivalents stood at $21.4 million with no debt as of March 31, 2026, down from $54.7 million a year ago.
Outlook and guidance
Focus remains on operational excellence, customer retention, and expanding market footprint through B2B relationships and membership programs.
Strategic partnerships, such as the agreement with Rural King, are expected to leverage pharmacy expertise and infrastructure.
Continued prioritization of website and user experience optimization and risk reduction.
Management highlighted sequential quarterly sales growth in Q4 and ongoing efforts to stabilize the core business and reduce costs.
- Sales dropped 22.7% and a $26.7M goodwill impairment led to a $34.2M net loss.PETS
Q1 202617 Feb 2026 - Sales and margins fell sharply, with a $53M net loss and major impairments amid ongoing headwinds.PETS
Q3 202617 Feb 2026 - Net sales fell 13% but net income rose to $3.8M, aided by a one-time stock comp reversal.PETS
Q1 20252 Feb 2026 - Q4 sales up 6.6% to $66.5M, but losses widened; focus on tech, efficiency, and growth.PETS
Q4 20241 Feb 2026 - Digital transformation, product expansion, and operational efficiency drive future growth.PETS
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Net sales dropped 16.1% to $59.6M, but margin and net income rose; dividend suspended.PETS
Q2 202516 Jan 2026 - Modernization, rebranding, and tech upgrades drive growth and recurring revenue in pet healthcare.PETS
27th Annual ICR Conference 202510 Jan 2026 - Sales fell 23.6% and a $26.7M goodwill impairment led to a net loss for the quarter.PETS
Q2 202619 Dec 2025 - Sales dropped 18.9% but gross margin and adjusted EBITDA improved on cost controls.PETS
Q3 202517 Dec 2025
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage